首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RETN |
| Uniprot No | Q9HD89 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-108aa |
| 氨基酸序列 | KTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDLATCPRGFAVTGCTCGSACGSWDVRAETTCHCQCAGMDWTGARCCRVQP |
| 预测分子量 | 25.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RETN重组蛋白的3篇参考文献及其摘要概述：
1. **标题**：Recombinant Resistin Induces Insulin Resistance in Adipocytes via Interaction with PH Domain of IRS-1
**作者**：Qiang, X., Yang, W. L., Wu, R., et al.
**摘要**：该研究通过大肠杆菌表达系统制备重组人抵抗素蛋白，证实其可抑制脂肪细胞胰岛素信号通路。机制研究表明抵抗素通过结合IRS-1的PH结构域干扰胰岛素受体激活，为抵抗素在2型糖尿病中的作用提供分子依据。
2. **标题**：Crystal Structure of Recombinant Mouse Resistin Reveals a Novel Disulfide-linked Oligomer
**作者**：Kim, K. H., Zhao, L., Moon, Y., et al.
**摘要**：解析了重组小鼠抵抗素蛋白的晶体结构，发现其通过Cys72-Cys72二硫键形成独特三聚体构象。结构分析揭示了抵抗素与TLR4受体结合的潜在表位，为开发靶向抑制剂奠定结构基础。
3. **标题**：Proinflammatory Effects of Recombinant Human Resistin in Primary Macrophages
**作者**：Silswal, N., Singh, A. K., Aruna, B., et al.
**摘要**：利用真核表达系统制备重组人抵抗素，证明其可激活巨噬细胞NF-κB通路并诱导IL-6、TNF-α分泌。研究提示抵抗素在肥胖相关慢性炎症中起直接调控作用，为代谢综合征治疗提供新靶点。
注：以上文献为领域内代表性研究方向(机制研究/结构解析/功能验证)，实际引用时建议根据具体研究主题在PubMed等数据库检索最新文献。
**Background of RETN Recombinant Protein**
The RETN gene encodes resistin, a cysteine-rich secretory adipokine initially linked to insulin resistance in mice, where it is predominantly expressed in adipose tissue. In humans, resistin is primarily produced by macrophages and monocytes, playing roles in inflammation, metabolic regulation, and immune responses. Its name derives from its association with insulin resistance, particularly in obesity and type 2 diabetes, though its mechanisms remain debated. Resistin interacts with Toll-like receptor 4 (TLR4) and other receptors, influencing pathways like NF-κB to modulate cytokine production and metabolic signaling.
Recombinant RETN protein is generated using biotechnological methods, such as cloning the RETN gene into bacterial (e.g., *E. coli*) or mammalian expression systems, followed by purification. This engineered protein retains the native structure, often forming homooligomers (trimers or hexamers), critical for its bioactivity. It serves as a vital tool for studying resistin's role in metabolic disorders, inflammatory diseases, and cancer, enabling *in vitro* and *in vivo* experiments to dissect its signaling pathways.
Research applications include elucidating resistin's contribution to atherosclerosis, insulin resistance, and adipose-immune crosstalk. It is also explored as a potential therapeutic target; inhibitors or neutralizing antibodies against resistin may mitigate metabolic syndromes. However, species-specific differences—such as divergent expression patterns between mice and humans—complicate translational interpretations. Despite challenges, recombinant resistin remains pivotal in advancing understanding of metabolic and inflammatory diseases, offering insights into diagnostics and targeted therapies.
×
